NRTX-1001
Phase 1- Indications
- Mesial temporal lobe epilepsy (MTLE)
Company intelligence / Profile preview
NeuroLambda Therapeutics
Cambridge, Massachusetts, United Statesneuronatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
NeuroLambda Therapeutics is a Cambridge-based biotech company founded in 2023. It operates in stealth mode and focuses on developing brain-penetrant small molecule therapeutics for neurological, inflammatory, and metabolic diseases. No clinical results or detailed pipeline information are currently public.
- Therapeutic areas
- Metabolic DisordersImmunologyNeurology
- Modalities
- Small molecules (specifically brain-penetrant small molecules)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NeuroLambda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroLambda Therapeutics.